The polygenic score snags a greater percentage of people at risk of early heart attack than current tests that rely on single-gene variants or blood chemistry.
One firm, Exosome Diagnostics, is working to streamline payor coverage for a commercial test, and researchers are simultaneously developing promising ways to isolate exosomes.
A microfluidic phone attachment developed at Brigham and Women's and Mass General may be the precursor of a fertility assay that men can use in the home.
